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Case Report
CA S E R E PORT
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Abstract
Neoantigen vaccines involving multi-peptides and poly-epitope-encoding RNA or DNA have undergone early phase clinical
testing with modest reported antitumor effects [1]. The less-than-expected activity of these neoantigenic vaccines may
correspond with the development of immune escape mechanisms. One permutation on neoantigen vaccines, which may
counter or prevent these adaptive immune escape mechanisms, are ‘personalized’ oncolytic viruses that encode one or
more tumor-specific transgenes. Herein, positive therapeutic effects for MY-NEOVAXTM, personalized neoantigen-enhanced
oncolytic adenoviruses, are described for two heavily pretreated end-stage patients, one with high-grade metastatic
neuroendocrine carcinoma of the pancreas and the other with colorectal cancer metastatic to the brain, liver and lungs. To
date, treatment benefit has exceeded 12 months without dose-limiting toxicities or related serious adverse events and with
documented radiologic stabilization and improved performance status.
INTRODUCTION
Neoantigen-based peptide,DNA,RNA and dendritic cell vaccines
have been used in the clinic, mostly in melanoma, with mixed
results. This less-than-expected efficacy has been attributed to
immune escape mechanisms [2], which include low neoanti-
gen burden, the immunosuppressive tumor microenvironment
and rapid epitope loss. Oncolytic viruses are an active form
of immunotherapy that are armed (or not) with therapeutic
transgenes such as granulocyte-macrophage colony stimulating
factor or interleukin (IL)-12 whose protein products are intended
to amplify antitumor immunity [3].
MY-NEOVAXTM is the proprietary name for patient-specific
replication conditional oncolytic adenovirus, which are engi-
neered and manufactured by EpicentRx, Inc., to carry up to
50 neoantigenic transgenes identified on next generation
sequencing (NGS). Unlike other neoantigen vaccines, these
personalized viruses have the potential to circumvent immune
escape mechanisms such as low antigen burden, epitope loss
and tumor-mediated immunosuppression because (i) every time
the virus replicates it also copies the therapeutic transgenes,
which leads to their overexpression and presumably drives
tumor-specific cytotoxic CD8+ T-cell responses against the
neoantigens even if the mutational load is low, (ii) insurance
462 M. Bouvet et al.
Figure 1: Simplified mechanism of oncolytic viruses armed with neoantigens.
against loss of one epitope multiple neoantigens are carried
and expressed by the virus and (iii) viral infection stimulates
the release of cytokines (IL-1, IL-6, IL-12, IL-18, IFN-γ and TNF-
α) and chemokines (RANTES, MIP-1α/β) that counteract local
and systemically induced immunosuppression and facilitate
the recruitment of effector T cells for the generation antitumor
immunity [4]. A simplified mechanism of neoantigen-armed
oncolytic viruses is illustrated in Fig. 1.
Two heavily pretreated end-stage patients, JM, a 30-year-old
male with high-grade metastatic neuroendocrine carcinoma of
the pancreas, and WB, a 64-year-old male with colorectal cancer
metastatic to the brain, liver and lungs, were treated with these
personalized oncolytic viruses i.e.MY-NEOVAXTM under separate
Food and Drug Administration- and Institutional Review Board-
approved compassionate use protocols. As described below, both
patients have demonstrated long-lasting disease stabilization
>12 months in the absence of any dose-limiting toxicities or
related serious adverse events. The specific transportation, han-
dling and administration requirements for MY-NEOVAX, which
are easily and routinely managed, have been described in a
separate publication [5].
CASE REPORTS
Case 1
The first patient, JM, is a 30-year-old male with high-grade
neuroendocrine carcinoma of the pancreas metastatic to the
retroperitoneum and cervical lymph nodes. Previous treatments
included cisplatin/etoposide to which he was refractory, the
experimental agent, RRx-001, to which he responded for over
a year and which primed a subsequent response to previously
refractory platinum etoposide, ipilimumab and nivolumab, to
which he was non-responsive, and a third retrial of platinum
etoposide that was ineffective. At the time of enrollment on
theMY-NEOVAXTM compassionate use protocol, his tumors were
rapidly progressing, and his functional performance status was
declining. Based on NGS profiling, a virus was Good Manufac-
turing Practice (GMP)-manufactured to carry several neoantigens
including the mutated gene for adenopolyposis coli (APC).
MY-NEOVAXTM has been administered intratumorally (IT) to
JV in an interventional radiology (IR) suite at a dose of 1×1012
in the retroperitoneum and cervical lymph nodes once every
2 weeks. Following the first dose of virus, immediately after
Figure 2: Shrinkage of a retroperitoneal mass circled in red with evidence of
necrosis on a 2-month CT scan.
which he experienced fever, myalgia, chills for 24 h, high levels
of virus were detected in the blood presumably from leakage
through injured tumor vasculature and/or from extrusion via
the injection track once the syringe was removed. This viremia
was cleared within 48 h; however, 1 week later a secondary
viremiawas observed presumably due to propagation of the viral
infection, with lysis and release of progeny viruses from the
infected tumor cells.
CT scans at 2 months after the initial treatment were read
as stable disease, but significant necrosis was detectable, likely
indicative of the direct oncolytic effect along with an approxi-
mately 18% tumor shrinkage (Fig. 2).
In addition, the patient has demonstrated a significantly
improved performance status, having been able to train for
and participate in long-distance ruck marches and marathon
bike rides. One serious adverse event (SAE), a fractured femur,
occurred when the all-terrain vehicle he was riding overturned
and landed on his leg. During open reduction and internal fixa-
tion surgery, no tumor was found in the femur.
Case 2
The second patient is a 64-year-old male, WB, with colorectal
cancer metastatic to the lungs, liver and brain. Previous
therapies included FOLFIRI/Erbitux, Xelox, Xeloda/Avastin, Rego-
rafenib, Erlotinib for brainmetastases and FOLFIRI/Avastin. From
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the FOLFIRI/Avastin, on which he progressed, WB experienced
Grade 4 neutropenia, severe diarrhea and rapid deterioration
prior to starting treatment with MY-NEOVAXTM. From the brain
metastases, cognitive dysfunction was present. Since Avastin
may predispose to hemorrhagic complications for several days
after its discontinuation, the decision was made to inject WB
subcutaneously with the virus at a dose of 5×1011, which
was GMP-manufactured to also carry the mutated gene for
adenopolyposis coli (APC) based on NGS, in the inguinal region
remote from any tumor.
Similar to the first patient, his CT scans were also read as
stable and his performance status markedly approved to the
point that he went from cognitively impaired and bedbound
to cognitively normal and fully participatory in tae-kwon-do
classes,where he recently earned a blue belt, which is two below
a black belt. He was treated for over 4 months with mild arthral-
gias as the only toxicity. A slight interval enlargement of his lung
tumors was seen on CT scan; although this enlargement was
attributed to pseudoprogression, it led to his discontinuation
from the trial; however, over 12 months later, after having been
restarted on chemotherapy, he remains largely stable.
DISCUSSION
The expected survival of last-line treatment refractory colorectal
cancer [6] and high-grade neuroendocrine carcinoma is less than
6months [7]. The present resultswith these two patients suggest
that MY-NEOVAX as monotherapy circumvented immunologic
tolerance. A Phase 1 study is planned in combination with other
immunotherapies. Biopsies have been performed, and when
their analysis is complete, results will be reported.
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